First-in-Class Type 2 Diabetes Treatment Glyxambi Tablets for Adults Now Available in US Pharmacies

Glyxambi (empagliflozin/linagliptin) tablets are now available by prescription in many leading chain and independent pharmacies across the US, including Walgreens and Rite Aid. Glyxambi, part of the Boehringer Ingelheim Pharmaceuticals and Eli Lilly and Company Diabetes alliance portfolio, is the first and only dual inhibitor combination therapy approved in the US to combine the mechanisms of action of a sodium glucose co-transporter-2 (SGLT2) inhibitor and a dipeptidyl peptidase-4 (DPP-4) inhibitor in a once-daily tablet.

Glyxambi is approved as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes (T2D) when both empagliflozin and linagliptin are appropriate treatments. Glyxambi is a once-daily tablet taken in the morning that combines 10 mg or 25 mg of empagliflozin, an SGLT2 inhibitor, with 5 mg of linagliptin, a DPP-4 inhibitor. Glyxambi is not for people with type 1 diabetes or for diabetic ketoacidosis (increased ketones in the blood or urine). 

"The rapid market availability of Glyxambi following its recent FDA approval in late January is a reflection of Boehringer Ingelheim and Lilly's commitment to bringing new treatment options to people with type 2 diabetes," said Kathleen Dowd, senior vice president, marketing, Boehringer Ingelheim Pharmaceuticals, Inc. "As the fourth diabetes medicine to emerge from our alliance pipeline in the US, we believe Glyxambi may help adults with type 2 diabetes lower their blood sugar and manage their diabetes."

"As an add-on to metformin, Glyxambi was superior in reducing A1C when compared with either empagliflozin or linagliptin alone," said David Kendall, vice president, medical affairs, Lilly Diabetes. "The management of type 2 diabetes requires a personalized treatment plan, and Glyxambi provides patients and their physicians with a new option to help improve blood sugar control."